Cargando…
Development of a novel small antibody that retains specificity for tumor targeting
BACKGROUND: For the targeted therapy of solid tumor mediated by monoclonal antibody (mAb), there have different models of rebuilding small antibodies originated from native ones. Almost all natural antibody molecules have the similar structure and conformation, but those rebuilt small antibodies can...
Autores principales: | Zhen, Zi-Peng, Zhang, Jie, Zhang, Si-Yuan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689864/ https://www.ncbi.nlm.nih.gov/pubmed/19405947 http://dx.doi.org/10.1186/1756-9966-28-59 |
Ejemplares similares
-
Solid Tumor-Targeted Infiltrating Cytotoxic T Lymphocytes Retained by a Superantigen Fusion Protein
por: Sun, Jialin, et al.
Publicado: (2011) -
Tumor-Targeting
Ability of Novel Anti-Prostate-Specific
Membrane Antigen Antibodies
por: Hsieh, Hsin-Hua, et al.
Publicado: (2022) -
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells
Publicado: (1986) -
Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy
por: ZHONG, GEN-SHEN, et al.
Publicado: (2013) -
Development of a novel bi-specific monoclonal antibody approach for tumour targeting
por: Koumarianou, A A, et al.
Publicado: (1999)